Structure Therapeutics Inc. American Depositary Shares GPCR
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-12T02:51:57.127Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-12T00:54:06.842828605Z
FundamentalsAlpha Vantage · ready · quarter 2026-09-30 · fetched 2026-11-12T02:50:24.279875+00:00
Structure Therapeutics Inc. American Depositary Shares options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 17.65 | 173.9% | 20.8% | |||
| 25Δ | 24.25 | 109.6% | 16.5% | 18.47 | 164.8% | 17.8% |
| 30Δ | 23.83 | 118.5% | 15.5% | 19.30 | 155.7% | 14.9% |
| 35Δ | 23.41 | 127.4% | 14.5% | 20.10 | 147.9% | 12.1% |
| 40Δ | 22.99 | 136.4% | 13.5% | 20.71 | 146.7% | 10.7% |
| 45Δ | 22.56 | 145.3% | 12.5% | 21.33 | 145.6% | 9.4% |
| 50Δ | 22.10 | 136.5% | 10.8% | 21.94 | 144.5% | 8.0% |
| 55Δ | 21.62 | 124.5% | 8.9% | 22.56 | 143.2% | 6.6% |
| 60Δ | 21.14 | 112.5% | 7.0% | 23.19 | 140.0% | 5.6% |
| 65Δ | 20.66 | 100.5% | 5.1% | 23.81 | 136.9% | 4.6% |
| 70Δ | 20.18 | 88.4% | 3.2% | 24.44 | 133.7% | 3.6% |
| 75Δ | 25.13 | 131.5% | 2.7% | |||
| 80Δ | 26.34 | 137.3% | 2.0% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 17.65
- IV
- 173.9%
- B/E move
- 20.8%
25Δ
- Pseudo strike
- 24.25
- IV
- 109.6%
- B/E move
- 16.5%
- Pseudo strike
- 18.47
- IV
- 164.8%
- B/E move
- 17.8%
30Δ
- Pseudo strike
- 23.83
- IV
- 118.5%
- B/E move
- 15.5%
- Pseudo strike
- 19.30
- IV
- 155.7%
- B/E move
- 14.9%
35Δ
- Pseudo strike
- 23.41
- IV
- 127.4%
- B/E move
- 14.5%
- Pseudo strike
- 20.10
- IV
- 147.9%
- B/E move
- 12.1%
40Δ
- Pseudo strike
- 22.99
- IV
- 136.4%
- B/E move
- 13.5%
- Pseudo strike
- 20.71
- IV
- 146.7%
- B/E move
- 10.7%
45Δ
- Pseudo strike
- 22.56
- IV
- 145.3%
- B/E move
- 12.5%
- Pseudo strike
- 21.33
- IV
- 145.6%
- B/E move
- 9.4%
50Δ
- Pseudo strike
- 22.10
- IV
- 136.5%
- B/E move
- 10.8%
- Pseudo strike
- 21.94
- IV
- 144.5%
- B/E move
- 8.0%
55Δ
- Pseudo strike
- 21.62
- IV
- 124.5%
- B/E move
- 8.9%
- Pseudo strike
- 22.56
- IV
- 143.2%
- B/E move
- 6.6%
60Δ
- Pseudo strike
- 21.14
- IV
- 112.5%
- B/E move
- 7.0%
- Pseudo strike
- 23.19
- IV
- 140.0%
- B/E move
- 5.6%
65Δ
- Pseudo strike
- 20.66
- IV
- 100.5%
- B/E move
- 5.1%
- Pseudo strike
- 23.81
- IV
- 136.9%
- B/E move
- 4.6%
70Δ
- Pseudo strike
- 20.18
- IV
- 88.4%
- B/E move
- 3.2%
- Pseudo strike
- 24.44
- IV
- 133.7%
- B/E move
- 3.6%
75Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 25.13
- IV
- 131.5%
- B/E move
- 2.7%
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 26.34
- IV
- 137.3%
- B/E move
- 2.0%
Options history
Table
| Date | IV (%) |
|---|---|
| 87.54% | |
| 95.74% | |
| 87.50% | |
| 81.56% | |
| 89.45% | |
| 87.22% | |
| 100.06% | |
| 91.21% | |
| 90.51% | |
| 90.13% |
Biotechnology
GRCE
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company is headquartered in…
More →GYRE
Gyre Therapeutics Inc. is a pioneering biopharmaceutical company at the forefront of developing advanced therapies for rare and complex diseases. Leveraging its proprietary…
More →HALO
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company is…
More →HELP
Cybin Inc., doing business as Helus Pharma, a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health…
More →HOWL
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapies designed to boost the body's immune system for the treatment of cancer. The company is headquartered…
More →HRMY
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and markets therapies for patients with rare neurological disorders. The company is…
More →